# Nobori Dual Antiplatelet Therapy as Appropriate Duration

Study · id `cardio:ct-nct01514227` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01514227](<https://clinicaltrials.gov/study/NCT01514227>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01514227

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3773 participants.

## Technical summary

Registry record NCT01514227. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2016-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3773 participants (enrolled count; ClinicalTrials.gov record NCT01514227, source copy `cardio:ctgov-nct01514227-2017-01-27`, retrieved 2026-10-26)
- Start date: 2011-12 (registry gives no type) (ClinicalTrials.gov record NCT01514227, source copy `cardio:ctgov-nct01514227-2017-01-27`, retrieved 2026-10-26)
- Primary completion: 2016-06 (actual) (ClinicalTrials.gov record NCT01514227, source copy `cardio:ctgov-nct01514227-2017-01-27`, retrieved 2026-10-26)
- Completion: 2016-06 (actual) (ClinicalTrials.gov record NCT01514227, source copy `cardio:ctgov-nct01514227-2017-01-27`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01514227, source copy `cardio:ctgov-nct01514227-2017-01-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01514227-2017-01-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Nobori Dual Antiplatelet Therapy as Appropriate Duration
- Condition: Coronary Artery Disease
- Intervention (Drug): Aspirin or thienopyridine
- Intervention (Drug): Aspirin and thienopyridine
- Lead sponsor: Associations for Establishment of Evidence in Interventions
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation (`cardio:pubmed-28641838`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1f64d5063f37398199f110449103370ef43a2f681bdead955c5650d2a88ae265
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
